LONDON, April 10, 2014 /PRNewswire/ --
On Wednesday, April 09, 2014, the
NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones
Industrial Average advanced 1.11% to 16,437.18, and the S&P 500
closed at 1,872.18, up 1.09%. The gains were broad based as eight
out of 10 sectors ended the session in positive. The S&P 500
Health Care Sector Index finished the day at 673.27, up 2.11%, and
the same has advanced 2.86% in the last three months. Investor-Edge
has initiated coverage on the following equities: Seattle Genetics
Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine
Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ:
MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be
downloaded upon signing up at:
http://www.investor-edge.com/1008-register
Seattle Genetics Inc.'s stock gained 2.87% on Wednesday, closing at
$42.27, after oscillating between
$41.14 and $42.62. A total of 1.33
million shares were traded, which is above its three months average
volume of 1.15 million shares. Seattle Genetics Inc.'s shares have
declined 18.37% in the last one month, while the same has advanced
2.22% in the previous three months and 5.97% on YTD basis. The
company's stock is trading below its 50-day and 200-day moving
averages. Seattle Genetics Inc.'s 50-day moving average of
$48.61 is above its 200-day moving
average of $43.01. Furthermore, the
company's stock has a Relative Strength Index (RSI) of 32.76. Sign
up today to read free research on SGEN at:
http://www.investor-edge.com/1008-SGEN-10Apr2014.pdf
Shares in Theravance Inc. witnessed a trading volume of 1.08
million shares on Wednesday, as compared with its three months
average volume of 0.96 million shares. The stock ended the day at
$29.62, up 2.28%, after trading
between $28.98 and $29.85. Shares in Theravance Inc. have gained
4.41% in the past three trading sessions, while the same has fallen
by 15.03% in the last one month and 16.91% on YTD basis. The stock
is trading below its 50-day and 200-day moving averages. Theravance
Inc.'s 200-day moving average of $36.88 is above its 50-day moving average of
$35.12. Additionally, the company's
shares have an RSI of 29.39. Sign up today to read free research on
THRX at:
http://www.investor-edge.com/1008-THRX-10Apr2014.pdf
On Wednesday, shares in Neurocrine Biosciences Inc. advanced 3.34%
finishing the session at $14.53. The
stock recorded a trading volume of 0.73 million shares which is
below its three months average volume of $1.17 million shares. The stock fluctuated
between $14.01 and $14.61 during the
session. Shares in Neurocrine Biosciences Inc. have declined 16.97%
in the last one month and 20.56% in the previous three months,
while the same has advanced 55.57% on YTD basis. The stock is
trading above its 200-day moving average. Neurocrine Biosciences
Inc.'s 50-day moving average of $16.79 is above its 200-day moving average of
$13.50. Moreover, the company's
shares have RSI of 33.29. Sign up today to read free research on
NBIX at:
http://www.investor-edge.com/1008-NBIX-10Apr2014.pdf
MiMedx Group Inc.'s stock recorded a trading volume of 0.38 million
shares, as compared with its three months average volume of 0.65
million shares. The stock ended Wednesday's session at $5.96, up 3.83%, and at an intraday trading range
of $5.61 and $6.00. MiMedx Group Inc.'s shares have lost
17.68% in the last one month and 31.81% on YTD basis. The stock is
trading below its 50-day and 200-day moving averages. MiMedx Group
Inc.'s 50-day moving average of $6.91
is above its 200-day moving average of $6.32. Further, the company's shares have an RSI
of 33.68. Sign up today to read free research on MDXG at:
http://www.investor-edge.com/1008-MDXG-10Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge